Analysts say that all the attention being paid to the healthy effects of resveratrol [1] should boost Sirtris' efforts to push through an IPO it hopes will raise up to $60 million. Sirtris is focused on advancing sirtuin drugs to treat metabolic disorders like Type 2 diabetes and other age and diet-related diseases. But with only one drug in an early-stage trial, Cambridge, MA-based Sirtris is heading for the market at a much earlier stage than most biotechs would contemplate these days.
- here's the AP report [2] on the Sirtris IPO
Related Articles:
Sirtris pockets $37M in venture funds. Report [3]
Sirtris, Helicos file IPOs. Report [4]
Resveratrol may boost longevity, health. Report [1]
Links:
[1] http://www.fiercebioresearcher.com/story/ingredient-in-wine-may-boost-longevity-health/2006-11-02
[2] http://business.bostonherald.com/businessNews/view.bg?articleid=189694
[3] http://www.fiercebiotech.com/node/2799
[4] http://www.fiercebiotech.com/story/sirtris-helicos-file-ipos/2007-03-01